Skip to content

The evaluation of isotretinoineffects on treatment of COVID-19 infections

The evaluation of isotretinoin effects on treatment of COVID-19 infections

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190624043993N3
Enrollment
50
Registered
2020-07-23
Start date
2020-08-22
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Virus identified

Interventions

Intervention 1: Intervention group: Patients with Covid-19 disease will receive 20 mg Isotretinoin twice daily along with the standard of care for 7 days. Intervention 2: Control group: Patients with

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive covid-19 test During first 48 hours of symptoms

Exclusion criteria

Exclusion criteria: Underlying hematologic disease Underlying liver disease Known allergy to Isotretinoin Pregnancy/lactation

Design outcomes

Primary

MeasureTime frame
Clinical Cure. Timepoint: Seven and 14 days after treatment initiation. Method of measurement: Clinical and laboratory evaluations.;Virological cure. Timepoint: Day 7. Method of measurement: PCR.;ABG findings. Timepoint: Day 7. Method of measurement: Laboratory assessment.

Secondary

MeasureTime frame
Radiological cure, organ dysfunction, death. Timepoint: Day 14. Method of measurement: Clinical and para-clinical data.;Organ dysfunction. Timepoint: Day 7. Method of measurement: Clinical and laboratory data.;Death. Timepoint: Day 28. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForoud Shahbazi

Kermanshah University of Medical Sciences

Foroud08@gmail.com+98 83 3426 6780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026